Balixafortide is a ring-shaped synthetic peptide that blocks CXCR4, a receptor that guides immune cells, stem cells and some cancer cells. It reached a Phase 3 breast cancer trial that was stopped in 2021. This guide covers its structure, mechanism, trials, reported side effects and status. Sources were checked on November 17, 2026.
Quick answer: Balixafortide, also called POL6326, is a CXCR4 antagonist first developed by the Swiss company Polyphor. It was tested for stem cell mobilization, heart attack recovery and breast cancer. The Phase 3 breast cancer trial did not improve outcomes. It is not FDA-approved.
Vitrapep does not sell balixafortide; this page is a reference summary of published research and regulatory information.
What is balixafortide?
Balixafortide is a cyclic peptide. PubChem’s chemical name describes a ring of 16 amino acids, closed head to tail. An extra disulfide bridge links the cysteines at positions 2 and 9. The ring includes two D-prolines and a non-standard amino acid, 2,4-diaminobutanoic acid (PubChem CID 138752609).
PubChem lists the formula as C84H118N24O21S2 and the molecular weight as 1,864.1 g/mol. A 2017 trial report calls it a “peptidic CXCR4 antagonist” (Karpova et al., 2017). Our guide to types of peptides explains cyclic designs like this one.
Balixafortide: key facts
| Fact | Detail |
|---|---|
| Structure type | Cyclic peptide, 16 residues, backbone ring plus one disulfide bridge |
| Class | CXCR4 antagonist |
| Molecular formula | C84H118N24O21S2 |
| Molecular weight | 1,864.1 g/mol |
| Development stage | Phase 3 in breast cancer terminated (2021); investigator-led Phase 1 in pancreatic cancer registered, not yet recruiting (2025) |
| Sponsor or developer | Polyphor (originator); Spexis AG (Phase 3 sponsor of record) |
How does balixafortide work?
CXCR4 is a chemokine receptor on the cell surface. The NCBI gene record says it is “specific for stromal cell-derived factor-1,” also called CXCL12 (NCBI Gene, CXCR4). The same record notes that CXCR4 is highly expressed in breast cancer cells.
Balixafortide blocks this receptor. In healthy male volunteers, balixafortide “induces efficient mobilization” of blood-forming stem and progenitor cells (Karpova et al., 2017).
In breast cancer, it was tested together with the chemotherapy drug eribulin. The approved peptide motixafortide also blocks CXCR4, but it is used for stem cell mobilization. Our explainer on how peptides work covers receptor blockers in general.
What is balixafortide being studied for?
Balixafortide is not approved by the FDA for any use. ClinicalTrials.gov lists nine studies that name it or its code. The main ones are below.
- stem cell mobilization in multiple myeloma, sibling donors and healthy volunteers, Phase 1 and 2 (for example NCT01841476, completed 2015);
- large ST-elevation heart attack, Phase 2, CATCH-AMI, 120 enrolled (NCT01905475, completed 2016);
- HER2-negative metastatic breast cancer with eribulin, Phase 1 (NCT01837095, completed 2018);
- HER2-negative breast cancer with eribulin, Phase 3, FORTRESS, 432 enrolled (NCT03786094, terminated 2021); and
- metastatic pancreatic cancer with cosibelimab, Phase 1, Cedars-Sinai (NCT06981806, not yet recruiting).
A further breast cancer study by MedSIR was withdrawn before enrolling anyone, with the reason “Funder decision” (NCT04826016).
What did the key trials show?
Phase 1 with eribulin. This single-arm human trial enrolled 56 patients with heavily pretreated HER2-negative metastatic breast cancer. Partial responses occurred in 16 of 54 evaluable patients (30%). There was no control group (Pernas et al., 2018).
Phase 3 FORTRESS. This randomized, open-label human trial compared balixafortide plus eribulin with eribulin alone. In the second-line-or-later group, median progression-free survival was 3.5 months versus 4.0 months. The hazard ratio was 1.10 (p = 0.445), showing no benefit. The registry states the study “was halted early due to failure to meet the primary endpoint” (NCT03786094). Polyphor had earlier announced that a co-primary response-rate endpoint was also not met (Polyphor, 2021).
What side effects have studies reported?
In the Phase 1 trial, the most common events of any grade included fatigue (79%) and reactions during treatment (48%). Serious adverse events affected 21 patients (38%), including febrile neutropenia in 5. Two patients died during treatment (Pernas et al., 2018).
In FORTRESS, posted results list 218 patients on the combination and 204 on eribulin alone. Serious adverse events occurred in 62 and 54, and deaths in 17 and 13. The clearest difference was acute reactions recorded at the time of treatment: 95 on the combination versus 0 on eribulin alone. Neutropenia, hair loss, nausea and weakness occurred at similar rates in both arms.
What is balixafortide’s regulatory status, and how is it used in research?
Balixafortide is an investigational drug. In April 2018, Polyphor announced that FDA granted Fast Track designation for balixafortide with eribulin in HER2-negative metastatic breast cancer (Polyphor, 2018). We found no FDA warning about it. The Cedars-Sinai Phase 1 was last verified in November 2025 and is listed as not yet recruiting.
In the lab, it serves as a CXCR4-blocking tool. A 2023 study reported that it enhanced docetaxel activity in a mouse model of prostate cancer bone metastasis (Robinson et al., 2023). A study at Yunnan Cancer Hospital, listed as recruiting, uses a fluorescent probe named ICG-POL6326 on breast cancer tissue samples (NCT06713161).
Frequently asked questions about balixafortide
Is balixafortide a peptide?
Yes. It is a cyclic peptide of 16 residues, including two D-prolines and one non-standard amino acid.
Is balixafortide FDA-approved?
No. Its Phase 3 trial was halted early, and no approval exists.
What is POL6326?
POL6326 is Polyphor’s research code for balixafortide.
How does balixafortide differ from motixafortide?
Both block CXCR4. Motixafortide is FDA-approved for stem cell mobilization; balixafortide has no approval.
Why did the Phase 3 trial stop?
The registry says it was halted early because it failed to meet its primary endpoint.
What to know now
- Structure: 16-residue cyclic peptide with a disulfide bridge; 1,864.1 g/mol.
- Mechanism: blocks the CXCR4 chemokine receptor; mobilizes stem cells in healthy volunteers.
- Evidence: FORTRESS Phase 3 showed no progression-free survival benefit (hazard ratio 1.10).
- Safety: acute treatment reactions were common with the combination.
- Status: not FDA-approved; Fast Track in 2018 per Polyphor; one investigator-led Phase 1 registered.
What we’re watching
Whether the Cedars-Sinai Phase 1 of balixafortide with cosibelimab in pancreatic cancer (NCT06981806) starts recruiting. Related guides: motixafortide and murepavadin, another Polyphor macrocycle.